Sign in
Taking people in BelgiumPhase 3

Long-term safety follow-up of patients treated with Galapagos CAR T-cell therapies

Checks long-term safety of CAR T-cell treatment in adults with blood cancers.

Key facts

Who runs it
Lakefront Biotherapeutics
Where
Edegem, Leuven, Liège, Roeselare, and Sint-Lambrechts-Woluwe, BelgiumSee the 5 sitesAlso in 3 other countries, 6 sites
Registry title
A long-term follow-up study for patients treated with Galapagos CAR T cell therapies
Status
Recruiting
Phase
Phase 3
People taking part
309 people, planned
Started
9 Sept 2024
Expected to end
20 Jul 2039
Type of study
Interventional
Record updated
11 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people who were treated with a Galapagos (GLPG) CAR T-cell therapy in a clinical trial or Managed Access Program. It follows their long-term safety.

Age
18 years or older
Sex
All sexes can join.
Earlier treatment
Must have been treated with a GLPG CAR T-cell therapy in a clinical trial or Managed Access Program.

Main reasons for not taking part

  • The record lists no exclusion criteria.

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Subject must sign and date the ICF as approved by the Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to any study-related procedures
  • Subjects has been treated with a GLPG CAR T-cell therapy in a clinical trial or Managed Access Program

Who cannot take part

  • There are no exclusion criteria for this study

Where in Belgium

Also in 3 other countries, 6 sites

  • Antwerp University HospitalEdegem, BelgiumTaking people
  • UZ LeuvenLeuven, BelgiumTaking people
  • Centre Hospitalier Universitaire de LiègeLiège, BelgiumTaking people
  • Algemeen Ziekenhuis DeltaRoeselare, BelgiumTaking people
  • Cliniques Universitaires Saint-LucSint-Lambrechts-Woluwe, BelgiumTaking people

About the trial

What the trial wants to find out

To evaluate the long-term safety of GLPG CAR T cell products for up to 15 years post CAR T cell product infusion

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A long-term follow-up study for patients treated with Galapagos CAR T-cell therapies
Plain-language title
Long-term safety follow-up of patients treated with Galapagos CAR T-cell therapiesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
11 September 2026